Hermes Pharma Expands Formulation Services to US Market

August 13, 2015
Pharmaceutical Technology Editors
PTSM: Pharmaceutical Technology Sourcing and Management
Volume 11, Issue 9

Companies in the US will now have the opportunity to tap into Hermes Pharma’s technical expertise in effervescent and chewable tablets, instant drinks, lozenges, and orally disintegrating granules (ODGs).

Hermes Pharma, a developer and manufacturer of user-friendly solid oral dosage forms, has announced plans to expand into the US market. The company specializes in making medicines easier to take.

From the development of new products through to regulatory support and manufacturing, Hermes Pharma provides customized solutions all along the pharmaceutical value chain. A newly formed team has been dedicated to serve the US market. Pharmaceutical and healthcare companies in the US will now have the opportunity to tap into Hermes Pharma’s technical expertise in effervescent and chewable tablets, instant drinks, lozenges, and orally disintegrating granules (ODGs).

A recent survey conducted by market research firm, Spiegel Institut Mannheim, and sponsored by Hermes Pharma, showed that half of the population in the US have difficulties swallowing their tablets or capsules. As a result, patients tend to chew, break up, crush, or dissolve their tablets before swallowing them. There are also concerns that some patients may even stop taking their medication, highlighting the impact of swallowing difficulties on patient compliance.

User-friendly dosage forms are easy to swallow and have a pleasant taste. They come in different flavors and convenient packaging. Hermes Pharma believes that user-friendly medication has a positive impact on patient compliance.  

Pharmaceutical companies looking to innovate can do so by introducing user-friendly alternatives of current and new drugs. This approach is one way to expand existing product lines or extend product lifecycles, while better meeting the needs of specific market segments (e.g., children and the elderly).

Source: Hermes Pharma